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Abstract: Adjuvants are key components in vaccines, they help in reducing the required antigen
dose but also modulate the phenotype of the induced immune response. We previously showed that
GPI-0100, a saponin-derived adjuvant, enhances antigen-specific mucosal and systemic antibody
responses to influenza subunit and whole inactivated influenza virus (WIV) vaccine administered
via the pulmonary route. However, the impact of the GPI-0100 dose on immune stimulation and the
immune mechanisms stimulated by GPI-0100 along with antigen are poorly understood. Therefore,
in this study we immunized C57BL/6 mice via the pulmonary route with vaccine consisting of
WIV combined with increasing amounts of GPI-0100, formulated as a dry powder. Adjuvantation
of WIV enhanced influenza-specific mucosal and systemic immune responses, with intermediate
doses of 5 and 7.5 µg GPI-0100 being most effective. The predominant antibody subtype induced by
GPI-0100-adjuvanted vaccine was IgG1. Compared to non-adjuvanted vaccine, GPI-0100-adjuvanted
WIV vaccine gave rise to higher numbers of antigen-specific IgA- but not IgG-producing B cells in
the lungs along with better mucosal and systemic memory B cell responses. The GPI-0100 dose was
negatively correlated with the number of influenza-specific IFNγ- and IL17-producing T cells and
positively correlated with the number of IL4-producing T cells observed after immunization and
challenge. Overall, our results show that adjuvantation of pulmonary-delivered WIV with GPI-0100
mostly affects B cell responses and effectively induces B cell memory.
Keywords: influenza; pulmonary immunization; adjuvant; immune mechanisms
1. Introduction
Adjuvants are important components of vaccines as they have the ability to enhance and to modify
the immune responses induced against an antigen. Many studies are ongoing to find effective mucosal
adjuvants and to elucidate the mechanisms by which they can help to reduce the antigen content in
a vaccine without compromising the immune response induced against the antigen itself. GPI-0100
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is one of such adjuvants; it is under preclinical investigation for use in parenteral and pulmonary
vaccines [1,2], and has been used in clinical tumor immunotherapy trials [3,4].
GPI-0100 is a semisynthetic triterpenoid saponin prepared by first deacylating a mixture of
Quillaja saponaria saponins and then coupling dodecylamine with the carboxyl group of the glucuronic
acid residue of the deacylated saponins through an amide bond [5]. GPI-0100 is a highly purified
analogue of QS-7, which also has immune-modulating properties [5,6]. GPI-0100 is more stable than
other Quillaja saponins and has a better safety profile [4]. The receptor for GPI-0100 is not known;
however, its adjuvant activity is believed to be mediated by the aldehyde group of the molecule and
might be related to its capacity to form pores in the lipid bilayer of cells. GPI-0100 has been shown to
stimulate Th1 immunity, cytotoxic T lymphocytes (CTL) responses, and antibody production against
co-delivered antigens [7]. Use of GPI-0100 as adjuvant for parenteral subunit or virosomal influenza
vaccines allowed induction of robust and protective immune responses in mice even at very low
antigen doses (8 ng) [1,2].
An attractive alternative to parenteral vaccination is pulmonary vaccine delivery. Pulmonary
vaccination is easy to perform, patient-friendly and capable of inducing immune responses at the portal
of entry of many pathogens [8]. Pulmonary vaccine delivery targets the lungs, which form a highly
vascularized organ with a large surface area that is under constant immune surveillance. Several small-
to large-scale human clinical trials demonstrate that pulmonary immunization in humans is safe and
feasible [9,10]. Recently, inhaled live attenuated measles vaccine formulated as aerosol or dry powder
was demonstrated to be safe and effective in a Phase I clinical trial [11].
The suitability of saponin-derived adjuvants for pulmonary immunization was first studied in
sheep by Wee and co-workers [12]. These authors showed that ISCOMATRIX, an adjuvant composed
of purified fractions of Quillaia saponaria extract (ISCOPREP saponin) along with cholesterol and
phospholipid, induced markedly increased lung and serum antibody titers to whole inactivated
virus (WIV) influenza vaccine that was delivered to the lower caudal lobe of the sheep lung.
In addition, ISCOMATRIX-adjuvanted pulmonary vaccine also induced long-term antibody and
memory responses [13]. We have earlier shown that immune responses to pulmonary-delivered
influenza subunit or WIV vaccine in mice could be significantly enhanced by inclusion of GPI-0100 as
adjuvant in both liquid and dry powder vaccine formulations [14,15]. Recently, we investigated in a
head-to-head comparison in mice four different adjuvants for a pulmonary-delivered WIV influenza
vaccine. Compared to the TLR ligands Pam3CSK4, MPLA and CpG, GPI-0100 was more potent in
inducing mucosal and serum antibodies. Moreover, mice immunized with WIV-GPI-0100 showed
reduced lung virus titers after challenge with heterologous influenza strain [15].
In this study, we evaluated in more detail the immune mechanisms induced by
pulmonary-delivered GPI-0100-adjuvanted influenza vaccine. To this end, we immunized mice twice
with WIV vaccines containing different doses of GPI-0100 and subsequently challenged them with live
virus. The vaccines were formulated as dry powders and were administered to the trachea of intubated
mice. Systemic and mucosal antibody responses as well as numbers of germinal center and memory B
cells, and cytokine-producing T cells were determined. Our results reveal that GPI-0100 in combination
with WIV mainly affects B cells and that an intermediate dose of the adjuvant is most effective.
2. Materials and Methods
2.1. Virus and Vaccine Preparation
Influenza strain A/Puerto Rico/8/34 H1N1 (A/PR/8) was cultured in embryonated eggs and
WIV was produced by treating the sucrose gradient purified virus with 0.1% β-propiolactone as
described previously [16,17]. GPI-0100 was purchased from Hawaii Biotech (Honolulu, HI, USA).
GPI-0100-adjuvanted vaccine solutions were prepared by adding different amounts of GPI-0100 to
WIV vaccine solution (WIV:GPI-0100, w/w, 3:1, 3:2, 3:3 and 3:6). Vaccine solutions were later mixed
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with inulin solution to obtain a final concentration of 5% w/v inulin resulting in a protein:inulin ratio
of 3:200 w/w. This mixture was spray freeze dried as described previously [18].
2.2. Immunization, Challenge and Sample Collection
Animal experiments were approved by The Institutional Animal Care and Use Committee of the
University of Groningen (IACUC-RuG), The Netherlands (Ethical protocol number DEC 5879I). In vivo
experiments were performed in 6–8-week-old female C57BL/6 mice (Harlan, Zeist, The Netherlands).
Mice (n = 6/experimental group) were anaesthetized using isoflurane/O2 and vaccinated twice
via the pulmonary route, with an interval of 3 weeks as described previously [18]. Briefly, mice were
intubated using a modified Autoguard catheter (Becton Dickinson, Breda, The Netherlands) and
approximately 500 µg of powder vaccine containing 2.5 µg HA of A/PR/8 was delivered to the lungs
by applying a single puff of 200 µL using a dry powder insufflator (DPI, Penn-Century Inc., Wyndmoor,
PA, USA). Mice sublethally infected with A/PR/8 served as positive control. Sublethal infection was
done by gentle administration of 1000 TCID50 A/PR/8 in 2.5 µL phosphate buffered saline (PBS) to
the nostrils. Mice infected twice in this way developed robust antibody titers but no disease symptoms.
Untreated mice served as negative control.
Thirty days after the booster vaccination or the second sublethal infection, the effect of the
vaccines/previous infection on disease parameters was determined by total respiratory tract challenge
of the mice. To this end, a dose of 100 TCID50 A/PR/8 virus (10 LD50) was administered intranasally
in a total volume of 40 µL PBS as described previously [17]. Five days post challenge, mice were
sacrificed under isoflurane/O2 anesthesia. Blood, nose washes, bronchoalveolar lavages (BAL), lungs
and spleen were collected. Nose wash and BAL were collected using 1 mL PBS containing complete
protease inhibitor cocktail (Roche, Almere, The Netherlands). Lungs were perfused through the heart
using 20 mL PBS containing heparin. The right lobes of the lungs were collected in PBS with protease
inhibitor for virus quantification and stored on ice. The remaining parts of the lungs were collected
in complete Iscove’s Modified Dulbecco’s Medium (IMDM) with 1 mg/mL collagenase D (Roche,
Almere, The Netherlands) and processed as described previously to assess lymphocytes [19]. Spleens
were collected in complete IMDM and were processed to single-cell suspension using GentleMACS
C tubes and a GentleMACS dissociator (Mitenyi Biotec B, Leiden, The Netherlands) and stored in
ice. Later, red blood cells were lysed using ACK buffer (0.83% NH4Cl, 1 mM KHCO3, 0.1 mM EDTA,
pH 7.2). ELISpot and flow cytometry were performed using splenocytes from individual mice or lung
lymphocytes pooled per experimental group.
2.3. ELISA
Two hundred microliter of nose washes and bronchoalveolar lavages (BAL) were used for analysis
of mucosal antibody responses. Serum samples were diluted 1:100 and 200 µL was used for evaluation
of humoral immune responses. Influenza-specific IgG, IgG1, IgG2c and IgA antibody titers were
determined by ELISA as previously described [18]. IgG titers were calculated as the reciprocal of
the dilution resulting in an optical density (OD) of 0.2. Since for IgA in nose wash an OD of 0.2 was
not reached in all cases, a titer could not be calculated; antibody amounts are depicted as OD492
values instead.
2.4. Virus Titration
Collected lungs were homogenized in PBS (pH 7.4) followed by centrifugation at 1200 rpm for
10 min at 4 ◦C. Lung homogenate supernatants were collected, snap-frozen in liquid nitrogen and
stored at −80 ◦C until use. Lung virus titers were determined by infecting MDCK cells grown in
96-well plates as described previously [16]. Virus titers are presented as log10 titer per gram lung tissue.
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2.5. ELISpot
B cell ELISpot was performed as previously described with some modifications [20]; 5 × 105
lymphocytes from lungs or splenocytes were added to MultiScreenHTS-HA filter plates (Millipore,
Billerica, MA, USA) uncoated or coated with 10 µg/mL A/PR/8 subunit vaccine. Plates were incubated
overnight at 37 ◦C with 5% CO2 in IMDM complete medium. Subsequently, alkaline phosphatase
labeled anti-mouse IgA antibody (Sigma-Aldrich Chemie B.V., Zwijndrecht, The Netherlands) or
horse radish peroxidase labeled anti-mouse IgG antibody (Southern Bio-tech, Birmingham, AL, USA)
was added to the wells. The numbers of IgA- and IgG-secreting cells (ASC) were quantified using
5-bromo-4-chloro-3′-indolyphosphate p-toluidine/nitro-blue tetrazolium chloride (BCIP/NBT) and
3-amino-9-ethylcarbazole (AEC) substrate (Roche, Almere, The Netherlands), respectively.
Influenza-specific IFNγ-, IL4- and IL17-producing T cells were enumerated by ELISpot using
a murine IFNγ ELISpot kit (Gen-Probe Diaclone SAS, Besancon Cedex, France), an in-house IL4
ELISpot protocol, or an IL17 ELISpot kit (eBioscience, Vienna, Austria), respectively. Briefly, 5 × 105
lymphocytes from lungs or splenocytes were added to MultiScreenHTS-HA filter plates (Millipore,
Billerica, Massachusetts) coated with anti-IFNγ, anti-IL4 (BD Biosciences, Breda, The Netherlands)
or anti-IL17 antibodies. Plates were incubated overnight at 37 ◦C with 5% CO2 in IMDM complete
medium without or with 10 µg/mL WIV obtained from A/PR/8. For IFNγ and IL17 ELISpot, staining
was done as per the manufacturer’s instructions. IL4-producing cells were detected using alkaline
phosphatase-labelled anti-mouse IL4 antibodies (eBioscience, Vienna, Austria). Plates were washed
with PBS and spots were developed using BCIP/NBT substrate (Roche, Almere, The Netherlands).
The reaction was stopped by washing plates with tap water.
2.6. Flow Cytometry
To U-bottom 96-well plates (Corning Incorporated, New York, NY, USA) 1 × 106 splenocytes or
lung lymphocytes were added per well. After extensive washing with PBS, containing 0.1% bovine
serum albumin, cells were centrifuged at 1200 rpm for 5 min at 4 ◦C and blocked with Fc Block
(BioLegend, San Diego, CA, USA). Pelleted cells were resuspended and for B cell analysis stained with
anti-IgM PeCy7, anti-GL7 eFluoro 660, anti-CD38 eFluro 450 (all antibodies from eBioscience, Vienna,
Austria), anti-IgD PeCy7, anti-CD138 PerCpCy5.5 and anti-B220 BV605 (BioLegend, San Diego, CA,
USA) diluted in FACS buffer at 4 ◦C for 60 min. Cells were then washed and analyzed using a BD FACS
VerseTM flow cytometer (BD Biosciences, Breda, The Netherlands). Obtained data was analyzed using
Kaluza flow cytometry analysis software version 1.2 (Beckman Coulter, Woerden, The Netherlands).
2.7. Statistical Analysis
Since the data do not follow Gaussian distribution, the non-parametric Mann–Whitney U test was
used. One research question was to study whether addition of GPI-0100 to WIV results in an increase
of the humoral response. With the null hypothesis being that there is no statistically significant increase
in humoral responses by the GPI-0100 dose in question, we performed a one-tailed Mann–Whitney U
test for comparison of mice immunized with different amounts of GPI-0100 versus the non-adjuvanted
vaccine. Two-tailed Mann–Whitney test was used to analyze cytokine-producing cells with null
hypothesis being there is no statically significant increase or decrease in various cytokine-producing
cells by GPI-0100. p values < 0.05 were considered to represent statistically significant differences;
* and ** signify p < 0.05 and p < 0.01, respectively.
3. Results
3.1. Systemic Antibody Responses
Previous studies on pulmonary delivery of GPI-0100 along with influenza subunit or WIV vaccine
demonstrated that GPI-0100 is a potent adjuvant for induction of humoral responses [14]. To find out
more about the effect of GPI-0100 dose and how it affects the type of immune responses, in this study,
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mice were immunized twice with WIV alone or WIV admixed with different amounts of GPI-0100.
Mice infected intranasally with a sub-lethal amount of virus served as a positive control. On day 28
after the last immunization, the mice were challenged with A/PR/8 virus. On day 5 after challenge,
the day of sacrifice, all naïve control mice had substantial amounts of virus in the lung (average log10
virus titer/g lung tissue 5.5 ± 0.22 SEM) and all but one showed weight loss (Appendix Figure A1).
In contrast, all immunized animals, except one mouse immunized with non-adjuvanted WIV, were
completely protected from virus growth in the lungs. In none of the immunized groups did we observe
statistically significant weight loss over the infection period, although in the WIV, 2.5 µg GPI, and 5 µg
GPI group 3, 1 and 2 out of 6 mice, respectively, experienced some weight loss. Thus, irrespective of
the use of adjuvants pulmonary immunizations with WIV elicited immune responses which protected
the mice from virus growth in the lungs and from clinical symptoms.
After a single administration, none of the vaccines was able to induce IgG antibodies to the levels
found in mice given a sub-lethal influenza virus infection which served as a positive control (Figure 1A,
day 21). However, after the booster dose, which was given 21 days after the first dose, there was an
increase in IgG titers by 1–3 log in all immunized mice. By day 51, IgG levels in mice immunized with
non-adjuvanted WIV were still significantly lower than in convalescent mice (p = 0.0411). GPI-0100
increased vaccine-induced IgG titers in a dose-dependent manner; by day 28 (7.5 µg GPI-0100) or
day 51 (all adjuvanted vaccines), IgG levels in mice immunized with adjuvanted vaccines no longer
differed significantly from those in convalescent mice. Moreover, IgG levels elicited by vaccines
adjuvanted with 7.5 or 15 µg GPI-0100) were significantly higher than those elicited by non-adjuvanted
vaccine (Figure 1B). No increase in IgG antibody titers was observed 5 days after virus challenge, i.e.,
on day 56, neither in naïve nor in vaccinated animals. In line with previous observations with A/PR/
8 vaccines [14], HI titers were generally low (<40) even after two immunizations (Appendix Figure A2).
HI titers increased slightly after challenge in the 5, 7.5 and 15 µg GPI-0100 groups but not in the 2.5 µg
GPI-0100 group and the group immunized with non-adjuvanted vaccine.
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Figure 1. Effect of GPI-0100 on systemic antibody responses. Mice (n = 6 per group) were immunized
via the pulmonary route on day 0 and 21 with powder vaccines containing A/PR/8 whole inactivated
virus (WIV) (2.5 µg HA) alone or with the indicated amounts of GPI-0100. As a positive control, mice
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were sub-lethally infected by nose-restricted administration of 1000 TCID50 A/PR/8 on day 0 and
21. Control mice (ctrl) were non-immunized. On day 51, all mice were challenged with 100 TCID50
of A/PR/8 administered to the total respiratory tract. (A) A/PR/8-specific IgG responses evaluated
in serum collected on days 21, 28, 51 and 56. Mean group titers calculated from individual titers are
depicted. Arrow indicates day of challenge. (B) IgG, (C) IgG1 and (D) IgG2c after two immunizations.
IgG antibody levels are expressed as log10 titers. IgG1 and IgG2c levels are shown as µg/mL. Results in
B, C and D are shown as box and whisker plots depicting the median, mean, maximum and minimum
of the group. Levels of significance are presented as * p < 0.05, ** p < 0.01.
Quantification of IgG subclasses (Figure 1C,D) demonstrated that mice immunized with
GPI-0100-adjuvanted formulations developed higher levels of influenza-specific IgG1 antibody than
mice immunized with non-adjuvanted vaccine. Enhancing effects of GPI-0100 were highest for the
5 and 7.5 µg GPI-0100 groups; unexpectedly, mice immunized with 15 µg GPI-0100 had rather low
levels of IgG1. However, the variation within the experimental groups was high and the difference
in IgG1 levels as compared to the group immunized with non-adjuvanted vaccine was significant
only for the 5 µg GPI-0100 group. Analysis of IgG2c levels revealed that GPI-0100 had hardly any
effect on induction of this antibody subclass irrespective of the GPI-0100 dose used; most of the mice
given GPI-0100 adjuvanted WIV had IgG2c levels similar to those induced by non-adjuvanted WIV.
In contrast, sub-lethally infected mice developed robust IgG2c responses which exceeded IgG1 levels
in these animals. No influenza-specific IgG1 or IgG2c were found in the non-immunized control mice.
3.2. Mucosal Antibody Responses
The ability of GPI-0100 to boost the mucosal antibody response was evaluated in nose wash and
BAL of immunized and challenged mice (Figure 2). Quantification of antibody in the nose washes
(Figure 2A) showed that GPI-0100 positively affected nasal IgA responses. However, the enhancing
effect was limited and reached significance only in the 7.5 and 15 µg GPI-0100 groups. Irrespective
of the use of adjuvant, the vaccine-induced nose IgA responses were much lower than the responses
induced by infection. A similar trend as for nose IgA titers was observed for IgA and IgG antibodies in
the BAL (Figure 2B,C). Mean titers increased up to a dose of 7.5 µg GPI-0100; differences as compared
to titers in the WIV-alone group being significant for the 7.5 µg group (BAL IgA) and 5 µg group
(BAL IgG). The amount of IgA present in the lung was much higher than in the nose. Moreover,
BAL IgA and IgG levels in mice immunized with vaccines adjuvanted with 5 or 7.5 µg GPI-0100 were
similar to levels in sublethally infected mice. No IgA was found in the non-immunized but challenged
control group, indicating again that the infection did not have substantial effects on antibody responses
within the 5-day period post challenge.Vaccines 2017, 5, 19  7 of 16 
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and challenged as described in the legend to Figure 1. Nose washes and bronchoalveolar lavages 
(BAL) were collected 5 days after challenge with A/PR/8, i.e., on day 56 and were analyzed for (A) 
nose IgA; (B) BAL IgA; and (C) BAL IgG. IgA responses in the nose wash are presented as absorbance 
at OD492 while BAL IgA and IgG antibody levels are expressed as log10 titers. Live virus = sublethally 
infected, challenged mice. Ctrl = non-immunized but challenged mice. Results are shown as box and 
whisker plots depicting the median, mean, minimum and maximum of the experimental group. 
Levels of significance are presented as * p < 0.05, ** p < 0.01. 
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infection. Numbers of splenic B cells producing influenza-specific IgA were even lower and similar 
to those found in non-immunized, challenged control mice (Figure 3A, grey bars). Differences 
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However, IgA ASC were more abundantly present in all but the non-immunized control group and 
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infected, challenged mice. Ctrl = non-immunized but challenged mice. Results are shown as box and
whisker plots depicting the median, mean, minimum and maximum of the experimental group. Levels
of significance are presented as * p < 0.05, ** p < 0.01.
3.3. nalysis of ell espo ses
I order to determine the effect of GPI-0100 on the number of IgG- and IgA-producing B
cells in the spleens and lungs found after challenge, antigen-specific B cell ELISpot assays were
performed (Figure 3A,B). ELISpot results highlight that the number of spleen-resident B cells
producing influenza-specific I G was generally small and did not differ significantly between gr s
i i e it non-adjuvanted or GPI-0100-adjuvanted IV, respectively (Figure 3 , white bars).
I - r ci cells ere f i -i i e t c lle e c tr l ice. is i ic tes
t at the antibody-secreting B cells present w re the result of the prior vaccination rather than of
th infection. Numbers of splenic B cells producing influenza-specific IgA were even lower and
similar to those fou d in non-immunized, challenged c ntrol mice (Figure 3A, grey bars). iffere ces
t een ice i nized ith a juvanted and non-adjuvanted vaccine were therefore irrelevant.
l s l t ll i f ct ic s s st ti l rs f I s i t s l .
I t e l s, the nu bers of Ig SC ere again lo for all groups (Figure 3B, hite bars).
e er, I r r tl r s t i ll t t -i i c tr l r
t e r i i it - j te I ( i r , r rs). I ll r s i i
it adjuvanted vaccine, the number of IgA-producing cells was higher t an in the group immunized
with non-adjuva ted vaccine. The numbers of IgA ASC in the lungs of mice vaccinated with 2.5, 5,
7.5 and 1 µg GPI-100 were approximately 13-, 8-, 10- and 2-fold higher than in the mice that received
non-adju anted WIV. IgA ASC numbers in the groups that rec ived GPI-0100-adju anted vaccine
exceeded those found in lungs of sublethally infected mice (except for the 15 µg GPI-0100 group).
Furthermore, the lungs of mice immunized with GPI-0100-adjuvanted formulations contained more
antigen-specific IgA ASC than IgG ASC, while in the mice that received WIV alone, more IgG ASC
than IgA ASC were detected.
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(BALT) [21]. To find out whether GPI-0100 had an effect on the number of B cells present in germinal 
centers, we enumerated in spleens and in lungs class-switched B cells carrying the germinal center 
marker GL7 [22,23] (Figure 4A,B). In general, the percentages of GL7+ cells among class-switched 
(IgM-IgD-B220+) B cells were low and there was no consistent difference in the number of these cells 
(neither in spleen nor in lungs) between mice immunized with WIV in absence or presence of GPI-
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Figure 3. Effect of GPI-0100 on antigen-specific B cell responses. Effects of GPI-0100 dose on the
numbers of A/PR/8 HA-specific B cells were evaluated in the mice described in the legend to Figure 1
five days after challenge. Splenocytes (A) and lung lymphocytes (B) were harvested and incubated
overnight in plates coated with A/PR/8 subunit vaccine. The numbers of influenza-specific IgG (white)-
and IgA (grey)-producing cells from (A) spl en and (B) lung were calcula ed by subtrac ing the number
of spots formed in non-co ted w lls from the nu b r of spots for ed in coated wells. Live virus
= sublethally infected, challenged mice. Ctrl = non-immunized, challenged mice. Splenocytes were
analyzed for individual mice and data are depicted as box and whisker plots per experimental group.
Lung lymphocytes were pooled per experimental group and data are depicted as mean + SEM of
triplicate wells.
Development of high-affinity memory B cells takes place in specialized lymphoid structures
called germinal centers (GC). In the lungs, GC are found in bronchus-associated lymphoid tissue
(BALT) [21]. To find out whether GPI-0100 had an effect on the number of B cells present in germinal
centers, we enumerated in spleens and i lungs class-switched B cells carrying th g rminal center
marker GL7 [22,23] (Figure 4A,B). In ge eral, th p rcentages of GL7+ c lls among cl s-switched
(IgM−IgD−B220+) B cells were low and there was no consistent difference in the number of these cells
(neither in spleen nor in lungs) between mice immunized with WIV in absence or presence of GPI-0100,
nor between immunized mice and convalescent or naïve mice (Figure 4A,B, white bars). In contrast,
the percentages of CD38+ memory B cells (delineated as CD38+B220+IgM−IgD− [24,25]) in spleens as
well as in lungs were increased by GPI-0100, irrespective of the dose used (Figure 4A,B, grey bars).
Percentages of memory B cells in mice immunized with adjuvanted vaccines were equal to those in
infected mice. Enumeration of long-lived plasma cells (CD138+B220+IgM−IgD−) did not reveal any
effect of immunization and infection on this cell type, neither in spleen nor in lung [26].
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Figure 4. Effect of GPI-0100 on germinal center and memory B cell responses. Effects of GPI-0100 dose
on germinal center (white) and memory (grey) B cells were evaluated in (A) splenocytes and (B) pooled
lung cells of the mice described in the legend to Figure 1 five days after challenge. B cells in germinal
centers were evaluated by determining the percentage of GL7+ cells among total class-switched B cells
(B220+IgM−IgD−). Similarly, memory B cells were evaluated by determining the percentage of CD38+
cells among total class-switched B ce ls. Live virus = sublethally infected, challe ged mice; trl = naïve,
challenged mice. Splenocytes were analyzed for individual mice and data are depicted as box and
whisker plots per experimental group. Lung lymphocytes were pooled per experimental group. Levels
of significance are presented as * p < 0.05, ** p < 0.01.
3.4. Analysis of Cytokine Responses
We earlier observed that GPI-0100-adjuvanted vaccine administered via the pulmonary route
induces IL4-secreting T cells but hardly any IFNγ-secreting T cells ([15] and unpublished observations).
We now evalu ted the effect of imm nization on the cytokine r spons found after challenge as this
might affect or reflect clinical symptoms. For this purpose, we immunized mice with non-adjuvanted
and GPI-0100-adjuvanted WIV and analyzed the numbers of IFNγ-, IL4- and IL17-secreting cells in
both spleen and lungs five days after challenge with live influenza virus (Figure 5).
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Figure 5. Effect of GPI-0100 on antigen-specific cellular immune responses. Effects of GPI-0100 dose on
the number of A/PR/8-specific T cells were evaluated in the mice described in the legend to Figure 1
five days after challenge. Splenocytes (A) and lung lymphocytes (B) were incubated overnight with
or without A/PR/8 WIV. Th umbers of IFNγ- (gr y), IL4- (white) and IL17- (black) pro ucing
influenza-specific cells in spleen a d lung were calculated by subtracting the number of spots formed
by non-stimulated cells from the number of spots formed by stimulated cells. Live virus = sublethally
infected, challenged mice; ctrl = naïve, challenged mice. Results are expressed as spot-forming cells per
5 × 105 cells. Splenocytes were analyzed for individual mice and data are depicted as mean + SEM.
per experimental group. Lung lymphocytes were pooled per experimental group and data are depicted
as mean +SEM. of triplicate wells.
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High numbers of IFNγ-secreting cells were found in the spleens of all challenged animals
(>200/5 × 105 splenocytes). In mice immunized with GPI-0100-adjuvanted vaccines, the numbers
of IFNγ-secreting cells were lower than in mice receiving WIV alone. This trend was GPI-0100
dose-dependent; yet, significance was only reached for the 15 µg adjuvant group. As expected,
the spleens of sublethally infected, challenged mice contained high numbers of IFNγ-producing T
cells. Substantial numbers were also found in the spleens of naïve mice 5 days after influenza virus
challenge, indicating induction of IFNγ-producing cells by the infection.
Contrary to IFNγ-secreting cells, the number of IL4-secreting cells was increased in mice
immunized with GPI-0100-adjuvanted WIV as compared to mice immunized with WIV alone. Mice in
the 5 or 7.5 µg GPI-0100 groups had approximately three-fold more IL4-producing cells in the spleen
than mice immunized with WIV alone (significant for 5 µg GPI-0100) while lower and higher amounts
of the adjuvant had no effect. IL17-producing cells were present in spleens with low to very low
frequency. Low doses of GPI-0100 (2.5 and 5 µg) increased the number of the IL17-producing cells
significantly but due to the low overall numbers the relevance of this observation is unclear.
In the lungs, as in the spleens, the number of IFNγ-secreting cells decreased with increasing
doses of GPI-0100; yet, the dose dependency was much stronger and no IFNγ-secreting cells were
present in the lungs of mice from the 15 µg GPI-0100 group (Figure 5B). The naïve control group
displayed substantial numbers of IFNγ-secreting cells, most probably representing T cells induced
by the live virus infection given 5 days prior to sacrifice. The numbers of IL4-secreting cells in the
lungs were generally high as compared to the numbers in the spleen. Immunized mice displayed
much higher numbers of IL4-secreting cells in the lungs than previously infected and naïve, challenged
mice. GPI-0100 did not affect these numbers except for the 15 µg GPI-0100 dose for which the level of
IL4-secreting cells was low. Analysis of IL17-secreting cells from lungs showed that, compared to mice
given WIV alone, mice immunized with 2.5, 5 or 7.5 µg GPI-0100 had approximately 12-, 11- and 5-fold
more IL17-secreting cells. In mice immunized with 15 µg GPI-0100, the number of IL17-secreting cells
was similar to that in the WIV alone group and the previously infected group.
Overall the analysis of cytokine-secreting cells in immunized and challenged mice indicates
that GPI-0100 stimulates Th2 responses and suppresses Th1 responses in a dose-dependent manner.
Induction of Th17 cells benefits from low, but not from high, doses of GPI-0100.
4. Discussion
The immune response to vaccination is determined by the antigen-adjuvant combination and
the route of delivery. In previous studies, we showed that GPI-0100 is a potent adjuvant for
intramuscular-delivered as well as for pulmonary-delivered subunit or WIV influenza vaccine [1,14,15].
In this study, we aimed to get more insight in the immune mechanisms stimulated by GPI-0100
adjuvantation of pulmonary-delivered dry powder vaccines and to determine the effect of the GPI-0100
dose on these immune mechanisms.
Pulmonary delivery of WIV with different amounts of GPI-0100 resulted in effective
influenza-specific mucosal and systemic immune responses. GPI-0100 enhanced systemic IgG1 and
mucosal IgA responses but had no effect on IgG2c responses. Compared to non-adjuvanted vaccine,
GPI-0100-adjuvanted WIV gave rise to more antigen-specific IgA- but not IgG-producing B cells in
the lungs along with better mucosal and systemic memory B cells responses. Intermediate doses of
5 µg or 7.5 µg GPI-0100 were most effective in enhancing humoral immunity. These doses of GPI-0100
were also optimal for stimulation of IL-4-producing T cells while the GPI-0100 dose was negatively
correlated with the numbers of IFNγ-producing T cells.
We observed that the influenza-specific serum IgG titers increased with the amount of GPI-0100
present in the vaccine formulation. These results are in line with earlier observations of others and
us, indicating that saponin-derived adjuvants delivered via the pulmonary route effectively stimulate
antibody responses to admixed antigen in mice and in sheep [12,14,15]. Although after the first
vaccination antibody titers elicited by GPI-0100-adjuvanted vaccines were low compared to titers
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induced by sub-lethal amounts of live virus, after two vaccinations, antibody titers equaled those in
convalescent mice. These observations confirm that GPI-0100 exhibits strong adjuvant function in
the lungs. Increased serum IgG responses in mice immunized with adjuvanted vaccines were not
correlated with significant increases in splenic influenza-specific ASCs. Probably, ASCs were rather
located in lymph nodes or in bone marrow four weeks after primary vaccination [27,28].
In line with previous observations, GPI-0100 did not change the IgG1-dominated antibody
response to pulmonary-delivered WIV [15,16]. This indicates that GPI-0100 was unable to alter
the anti-inflammatory Th2 microenvironment of the lungs, not even in C57Bl/6 mice, which are
regarded as a prototypical Th1-type mouse strain [29,30]. In contrast, Ashtekar and co-workers did
observe stimulation of IgG2a responses by GPI-0100 when immunizing mice by total respiratory tract
administration with a protein-based Francisella tularensis vaccine [31]. However, these authors used a
dose of 100 µg GPI-0100, which might explain their observations. Indeed it has been shown earlier
that at low doses GPI-0100 stimulates mainly IgG1 responses, whereas at high doses (≥50 µg) both
IgG1 and IgG2a responses are enhanced [7].
IgA is the predominant antibody at mucosal surfaces having the ability to neutralize free virus
and intracellular virus in epithelial cells, thus providing protection against influenza infection of the
respiratory tract [32]. Analysis of IgA in the nasal cavity highlighted that nasal IgA titers induced by
GPI-0100-adjuvanted WIV were low compared to those induced by live virus infection. Active virus
replication in the nasal cavity of infected mice leads to stimulation of antigen presenting cells (APC) in
the nasal-associated lymphoid tissue (NALT). This results in programming of B cells such that memory
B cells home to the nose, where upon infection they start to differentiate to IgA-producing plasma
cells [25,33,34]. In contrast, during pulmonary immunization, the nasal cavity is bypassed by the
vaccine which leads to stimulation of epithelial cells and APC in the lungs. In line with this, we found
that GPI-0100 was capable of promoting amounts of lung IgA comparable to those induced by live
virus infection. The high amounts of IgA correlated well with the presence of more influenza-specific
IgA ASC and enhanced numbers of resident memory B cells in the lungs of mice immunized with
adjuvanted vaccine. However, B cells primed in the lung might not have the capacity to home to
the nose upon infection, which would explain the low levels of nasal IgA in the immunized animals.
We observed that GPI-0100 enhanced the levels of lung IgG to levels elicited by live virus. However,
no differences were found in the number of lung ASC-producing influenza-specific IgG between mice
immunized with plain and with GPI-0100-adjuvanted vaccine. Presumably, most IgG reaches the
lungs by transudation from serum rather than being locally produced [35]. The relative contribution of
IgA and IgG in the lung to protection against influenza virus is not entirely clear. On the one hand,
IgA ASC were shown to proliferate rapidly upon reinfection [25]. On the other hand, IgG in the lung
was shown to be more important than IgA for protection against influenza [36].
Germinal centers (GC) are important for class-switching of B cells, somatic hypermutation,
generation of long-lived plasma cells and differentiation of memory B cells [37]. The number of splenic
GC has earlier been shown to correlate with memory B cell formation and longevity of antibody
responses upon immunization with adjuvanted antigen [38]. Moreover, pulmonary GC induced by
influenza infection were shown to contribute decisively to local immune responses and protection [39].
Pulmonary immunization with plain or GPI-0100-adjuvanted WIV induced only slight increases in
the number of GL7+ B cells in spleens and had no effect on the number of these cells in the lungs.
Since we analyzed lung and spleen cells five days after challenge with influenza virus, GC might have
been induced by the infection and these GC might have obscured earlier existing vaccine-induced
GC. Yet, the low number of GL7+ cells found in spleens and lungs does not support this hypothesis.
While GPI-0100 adjuvantation had little effect on GC B cells, it significantly increased the number of
CD38+ memory B cells in both spleens and lungs. Even the lowest adjuvant dose was effective in this
respect. Memory B cells, especially memory B cells in the lungs, have been associated with improved
protection from influenza infection [25].
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Adjuvants have the ability to qualitatively alter the immune response to an accompanying
antigen by driving APC to release sets of cytokines which promote polarization of naïve T cells
to distinct T-helper phenotypes [40]. IFNγ, IL4 or IL17 are key cytokines secreted by Th1, Th2 or
Th17 cells, respectively. Th1 and Th2 cells stimulate B cells to produce IgG2a/c and IgG1 antibodies,
respectively [37]. Th17 cells are implicated in recruitment of neutrophils to the lungs [41]. Recently,
it was shown that Th17 cells, which enter the germinal center cycle, can convert into IgA-inducing T
follicular helper (Tfh) cells [42]. We found a clear negative correlation between the GPI-0100 dose in the
vaccine and the number of IFNγ-producing T cells present in spleen and lungs. Yet, since T cells were
measured in immunized and challenged mice, it is unclear whether lower numbers of IFNγ-producing
T cells were due to poor induction by vaccination or, rather, reflected inhibition of virus replication
in the lungs. On the other hand, we found increased numbers of IL4-producing cells in the spleen
with increasing GPI-0100 doses, while in the lungs GPI-0100 had no effect on IL4-producing T cells.
Together with stimulation of IgG1 rather than IgG2c responses, these results suggest that at the doses
used GPI-0100 delivered via the pulmonary route promotes mainly Th2 responses. Previous studies
suggest that the microenvironment in the respiratory tract favors a Th2 immune response resulting
in release of IL2, IL4, IL5, IL10 and TGFβ [29,43]. Th17 responses were increased at low, but not at
higher, doses of GPI-0100 and effects were more pronounced in the lungs than in the spleens. However,
compared to IFNγ- and IL4-producing T cells, the numbers for IL17-producing T cells remained low.
Induction of IL17 cells has been shown to determine the fate of pathogens upon pulmonary infection
via neutrophil recruitment and promotion of IgA production [41,42]. The role of Th17 cells in influenza
is still debated. Several studies report Th17 cells or the presence of IL17 to be beneficial [44,45]. Yet,
other studies report a detrimental effect of vaccine-induced Th17 [46,47].
One aim of our study was to get insight into dose-dependent effects of GPI-0100. Interestingly,
most immune responses were found to be highest at intermediate doses of 5 and 7.5 µg GPI-0100.
In general, the doses chosen for our study were rather low compared to the amounts used by others.
We argued that in order to minimize the risk of detrimental effects of the saponin adjuvant on lung
tissue, the dose should be as low as possible. In earlier studies, we showed that a dose of 15 µg
GPI-0100 did not change the histological appearance of the lung and had no effect on the number
of infiltrating neutrophils and macrophages [14]. Nevertheless, we cannot exclude completely that
the low levels of antibody- and cytokine-secreting cells found in the 15 µg GPI-0100 group in the
current study are due to toxicity induced by the adjuvant. C57BL/6 mice might be more susceptible to
interventions in the lungs and thus to detrimental effects of the adjuvant than Balb/c mice used in our
previous studies. Indeed, C57BL/6 were shown to exhibit more pronounced recruitment of eosinophils
and neutrophils upon OVA exposure as compared to Balb/c mice [48]. Also, genetic heterogeneity
leads to differences in cytokine/chemokine release between C57BL/6 and Balb/C mice upon antigen
exposure which ultimately affect immune responses [30]. Despite the low amounts of GPI-0100 used,
the adjuvant had prominent effects on the induced immune responses, in particular on antibody and
B cell responses.
5. Conclusions
Our results show that GPI-0100, when administered together with antigen via the pulmonary
route, is an excellent adjuvant for modulating mucosal and systemic immune responses. GPI-0100
is capable of stimulating IgA responses in the respiratory tract by promoting resident IgA ACS in
the lungs. In addition, GPI-0100 enhances mucosal and systemic IgG responses. This is reflected by
increased numbers of memory B cells in the lung and spleen that can proliferate and differentiate
rapidly to antibody-secreting plasma cells upon pathogen encounter. Thus, GPI-0100 is a promising
adjuvant for use in pulmonary vaccines.
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Figure A2: Hemagglutination inhibition titers. Mice (n = 6 per group) were immunized via the 
pulmonary route on day 0 and 21 with powder vaccines containing A/PR/8 WIV (2.5 μg HA) alone or 
with the indicated amounts of GPI-100. As a positive control, mice were sub-lethally infected by nose-
restricted administration of 1000 TCID50 A/PR/8 on day 0 and 51. A/PR/8-specific hemagglutination 
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Figure A1. eight development after challenge. ice (n = 6 per group) were immunized via the
pulmonary route on day 0 and 21 with powder vaccines containing A/PR/8 WIV (2.5 µg HA) alone
or with the indicated amounts of GPI-0100. As a positive control, mice were sub-lethally infected
by nose-restricted administration of 1000 TCID50 A/PR/8 on day 0 and 21. On day 51, mice were
challenged with 100 TCID50 of A/PR/8 administered to the total respiratory tract and weight was
monitored daily until sacrifice on day 5. Open circles: WIV, filled grey circles: WIV + GPI-0100
(increasing adjuvant dose = darker shades), black circle: previously infected mice, open squares:
naïve control.
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Figure 2. e agglutination inhibition titers. ice (n = 6 per group) ere i unized via the
l o ary ro te on day 0 and 21 with powder vaccines containing A/PR/8 WIV (2.5 µg HA)
alone or with the indicated amounts of GPI-100. As a positive control, mice were sub-lethally
infected by nose-restricted administration of 1000 TCID50 A/PR/8 on day 0 and 51. A/PR/8-specific
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pooled s ra per experimental group are shown.
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